Page last updated: 2024-11-10

prostaglandin a2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin A2: RN given refers to (5Z,13E,15S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5280880
CHEMBL ID1084643
CHEBI ID27820
SCHEMBL ID2115595
MeSH IDM0262363

Synonyms (74)

Synonym
(+)-prostaglandin a(sup 2)
(5z,13e,15s)-15-hydroxy-9-oxoprosta-5,10,13-trien-1-oic acid
CHEBI:27820 ,
BRD-K34782918-001-02-5
MLS000069589 ,
prostaglandin a(sup 2)
nsc 165561
5,6-cis-pga(sup 2)
5-heptenoic acid, 7-(2-(3-hydroxy-1-octenyl)-5-oxo-3-cyclopenten-1-yl)- (van)
prosta-5,10-13-trien-1-oic acid, 15-hydroxy-9-oxo-, (5z,13e,15s)-
pga(sup 2)
brn 2221844
(155)-pga2
LMFA03010035
9-oxo-15s-hydroxy-5z,10z,13e-prostatrienoic acid
IDI1_033930
BSPBIO_001460
(z)-7-[(1r,2s)-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxo-cyclopent-3-en-1-yl]hept-5-enoic acid
prosta-5,10,13-trien-1-oic acid, 15-hydroxy-9-oxo-, (5z,13e,15s)-
medullin
prostaglandin a2
pga2
C05953
13345-50-1
(+)-prostaglandin a2
nsc-165561
5,6-cis-pga2
(15s)-pga2
NCGC00022061-04
NCGC00022061-03
smr000058790
NCGC00022061-05
(5z,13e,15s)-15-hydroxy-9-oxoprosta-5, 10,13-triene-1-oic acid
(z)-7-((1r,2s)-2-((e)-(3s)-3-hydroxyoct-1-enyl)-5-oxocyclopent-3-enyl)hept-5-enoic acid
362927F3-3A3E-47BC-84C3-C32A293AA956
HMS1989I22
BML1-F02
HMS1791I22
HMS1361I22
CHEMBL1084643
(z)-7-[(1r,2s)-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopent-3-en-1-yl]hept-5-enoic acid
prosta-5,10,13-trien-1-oicacid, 15-hydroxy-9-oxo-, (5z,13e,15s)-
k6vt5bdy9e ,
unii-k6vt5bdy9e
gtpl6279
(z)-7-[(1r,2s)-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxo-1-cyclopent-3-enyl]hept-5-enoic acid
dinoprostone impurity, (5z,13e,15s)-15-hydroxy-9-oxoprosta-5, 10,13-triene-1-oic acid- [usp impurity]
15(s)-hydroxy-9-oxo-5-cis-10,13-trans-prostatrienoic acid
dinoprostone impurity d [ep impurity]
SCHEMBL2115595
15(s)-hydroxy-9-oxo-5-cis-10,13-trans-prostenoic acid
15.alpha.-hydroxy-9-oxo-cis-5,10,trans-13-prostatrienecarboxylic acid
15(s)-prostaglandin a2
15.alpha.-hydroxy-9-oxo-cis-5,10,trans-13-prostatrienoic acid
HMS3402I22
HMS3648I11
pga2 (prostaglandin a2)
15a-hydroxy-9-oxo-cis-5,10,trans-13-prostatrienecarboxylic acid
15a-hydroxy-9-oxo-cis-5,10,trans-13-prostatrienoic acid
15a-hydroxy-9-oxo-cis-5,10,trans-13-prostatrienoate
15(s)-hydroxy-9-oxo-5-cis-10,13-trans-prostatrienoate
15(s)-hydroxy-9-oxo-5-cis-10,13-trans-prostenoate
15a-hydroxy-9-oxo-cis-5,10,trans-13-prostatrienecarboxylate
Q27088462
sr-01000946222
SR-01000946222-1
prostaglandin a2 (pga2)
DTXSID20864388
(~{z})-7-[(1~{r},5~{s})-2-oxidanylidene-5-[(~{e},3~{s})-3-oxidanyloct-1-enyl]cyclopent-3-en-1-yl]hept-5-enoic acid
CS-0059420
HY-113041
pga2(prostaglandin a2)
pga2;medullin
AKOS040755328

Research Excerpts

Overview

Prostaglandin A2 is a major constituent of the gorgonian Plexaura homomalla. There is evidence that its biosynthesis involves a noncyclooxygenase pathway.

ExcerptReferenceRelevance
"Prostaglandin A2 is a major constituent of the gorgonian Plexaura homomalla, and there is evidence that its biosynthesis involves a noncyclooxygenase pathway. "( Investigation of the allene oxide pathway in the coral Plexaura homomalla: formation of novel ketols and isomers of prostaglandin A2 from 15-hydroxyeicosatetraenoic acid.
Brash, AR; Song, WC, 1991
)
1.93

Treatment

ExcerptReferenceRelevance
"Prostaglandin A2 (PGA2) treatment induces growth arrest of most cells, and we have recently shown that, for breast carcinoma MCF-7 cells, this is correlated with an induction of the cyclin-dependent kinase inhibitor p21 and reduced cyclin-dependent kinase 2 activity. "( Role of p21 in prostaglandin A2-mediated cellular arrest and death.
Gorospe, M; Holbrook, NJ, 1996
)
2.09

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of dl-alpha-tocopheryl (vitamin E) succinate in combination with Prostaglandin A2 (PGA2) and sodium butyrate on mouse neuroblastoma cells (NBP2) in culture, according to the criteria of growth inhibition and morphological differentiation (neurite formation), was studied."( Effects of dl-alpha-tocopheryl succinate in combination with sodium butyrate and cAMP stimulating agent on neuroblastoma cells in culture.
Prasad, KN; Rama, BN, 1984
)
0.5
"The effect of heat in combination with DL-alpha-tocopheryl (vitamin E) succinate and adenosine 3', 5'-cyclic monophosphate (cAMP) stimulating agents on mouse neuroblastoma cells ( NBP2 ) in culture on the criterion of growth inhibition (due to cell death and inhibition of cell division) was studied."( Effect of hyperthermia in combination with vitamin E and cyclic AMP on neuroblastoma cells in culture.
Prasad, KN; Rama, BN, 1984
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Dose-response testing and baseline IOP measurements were done."( Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes.
Bito, LZ; Camras, CB; Lee, PY; Podos, SM; Wang, RF, 1990
)
0.28
" PGA2 treatment resulted in a rapid increase in [Ca2+]i with the dose-response relationship for Ca2+ mobilization consistent with that seen for the induction of all five genes."( Calcium mediates expression of stress-response genes in prostaglandin A2-induced growth arrest.
Carlson, SG; Choi, AM; Holbrook, NJ; Tucker, RW; Weigand, G, 1994
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins A
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (47)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via cyclooxygenases (COX)137
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency21.15460.044717.8581100.0000AID485294; AID485341
Chain A, CruzipainTrypanosoma cruziPotency10.00000.002014.677939.8107AID1476
phosphopantetheinyl transferaseBacillus subtilisPotency72.67960.141337.9142100.0000AID1490
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency2.51190.00137.762544.6684AID914; AID915
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.35480.28189.721235.4813AID2326
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.48130.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency22.38720.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
DNA polymerase betaHomo sapiens (human)Potency3.16230.022421.010289.1251AID485314
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.14990.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.00790.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency30.13130.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)IC50 (µMol)13.70000.100012.726563.0000AID521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)24.00000.00033.166210.0000AID482142
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346567Mouse TRPA1 (Transient Receptor Potential channels)2008Proceedings of the National Academy of Sciences of the United States of America, Aug-19, Volume: 105, Issue:33
Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1.
AID681106TP_TRANSPORTER: inhibition of EA-GS uptake (EA-GS: 0.2 uM,PGA2: 10 uM, in the presence of GSH) in membrane vesicles from MRP1-expressing DTY 168 yeast cells1997FEBS letters, Dec-08, Volume: 419, Issue:1
Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.
AID482142Activation of TRPA1 channel2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (157)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (37.58)18.7374
1990's46 (29.30)18.2507
2000's36 (22.93)29.6817
2010's12 (7.64)24.3611
2020's4 (2.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.06 (24.57)
Research Supply Index5.10 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.84%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other160 (98.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]